Name	Hyunsoo Cho
Current Position & Affiliation	Clinical Assistant Professor, Seoul National University Hospital
Country	Korea
Major Field	Multiple Myeloma Translational Research

Educational Background

2005-2011 – M.D., Yonsei University College of Medicine, Seoul, Republic of Korea.
2013-2015 – M.S., Yonsei University College of Medicine, Seoul, Republic of Korea.
2016-2019 – Ph.D. Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.

Professional Experience

2011-2016 – Internship & Residency, Severance Hospital, Seoul, Republic of Korea.
2016-2020 – Full-time PhD & Postdoctoral Researcher (Military Duty), Graduate School of Medical Science and Engineering (GSMSE), KAIST, Daejeon, Republic of Korea.
2020-2021 – Clinical Fellow, Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
2021 - 2025 – Assistant Professor, Same Department.
2025 – Current – Clinical Assistant Professor, Division of Hematology & Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

Other Experience and Professional Memberships

Korean Society of Hematology Precision Medicine Working Party committee member
Korean Society of Hematology CAR-T committee member
Korean Society of Blood and Marrow Transplantation Cord Blood and Cellular Therapy committee member
Korea Genome Organization committee member

Main Scientific Publications

1. Kim S, Kwak JE, Koh JY, Kook HW, Kim YR, Kim SJ, Kim JS, Cheong JW, Lee MG, Lee H, Shin EC, Kim K, Chung H, Choi IK*, Lee JS*, Cho H*. NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma. Blood. 2025 Jul 24;146(4):456-470.
2. Shin S, Kim YJ, Yun HG, Chung H, Cho H*, Choi S*. 3D amplified single-cell RNA and protein imaging identifies oncogenic transcript subtypes in B cell acute lymphoblastic leukemia. ACS nano 2024 Feb 6.
3. Kim SJ, Chung H, Kwak JE, Kim YR, Park CH, Kim Y, Cheong JW, Wu J, Shin EC*, Cho H*, Kim JS*. Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma. J Immunother Cancer 2024 Jan 8;12(1):e007886.
4. Cho H, Kim KH, Lee H, Kim CG, Chung H, Choi YS, Park SH, Cheong JW, Min YH, Shin EC,

Kim JS. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. Clin Cancer Res. 2021 May 15;27(10):2947-2958.
5. Cho H et al. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. Clin Cancer Res. 2021 May 15;27(10):2947-2958.